Loading...
XJPX
4596
Market cap23mUSD
Jul 10, Last price  
74.00JPY
1D
7.25%
1Q
-19.57%
Jan 2017
-92.91%
IPO
-92.56%
Name

Kubota Pharmaceutical Holdings Co Ltd

Chart & Performance

D1W1MN
XJPX:4596 chart
P/E
—
P/S
192.92
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.31%
Rev. gr., 5y
-10.80%
Revenues
21m
-21.53%
2,727,411,5703,704,241,13552,947,0003,746,666,6002,913,667,140846,254,00000037,786,00008,254,00039,887,00027,189,00021,335,000
Net income
-676m
L-49.26%
499,326,853333,368,9354,299,000-212,335,100-3,088,242,618-3,910,726,000-3,444,615,000-3,046,403,000-3,065,570,000-2,437,424,000-2,616,451,000-2,015,906,000-1,489,602,000-1,332,852,000-676,253,000
CFO
-581m
L-51.54%
34,823,784897,335,3397,246,000936,137,400-2,042,484,660-3,011,544,000-3,126,424,0000-3,195,573,000-2,169,163,000-2,495,762,000-2,069,933,000-1,335,000,000-1,199,207,000-581,138,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Kubota Pharmaceutical Holdings Co., Ltd., an international entity established in Tokyo, Japan, in 2002, focuses on the creation and advancement of a diverse range of pharmaceutical treatments and medical devices. A primary asset in their development pipeline is emixustat hydrochloride, a drug currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. Beyond its pharmaceutical endeavors, the company is also innovating in medical technology, specifically with a patient-centric ophthalmology suite designed for remote retinal monitoring. This advanced suite features both miniature, home-use optical coherence tomography (OCT) devices and high-resolution OCT technology adapted from NASA. Furthermore, Kubota Pharmaceutical Holdings is developing a wearable device aimed at controlling myopia.
URL
https://www.kubotaholdings.co.jp/
IPO date
Dec 06, 2016
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT